新型抗菌肽GA-C16G2的研制及其靶向变形链球菌的特性
本研究将没食子酸(GA)连接到靶向变形链球菌的抗菌肽C16G2上合成新型肽GA-C16G2,并体外评价其理化性质、细胞毒性和抗菌活性。GA-C16G2纯度为95.02%,在人工唾液中稳定、细胞毒性低,对变形链球菌的MIC为3.1 μM、MBC为20.8 μM,1分钟内使变形链球菌存活率降低97.22%,并抑制生物膜形成。
要点
- GA-C16G2对变形链球菌MIC为3.1 μM、MBC为20.8 μM,对共生菌作用较弱。
- 1分钟时GA-C16G2使变形链球菌存活率降低97.22%。
- GA-C16G2在人工唾液中稳定、对人牙龈成纤维细胞毒性低,并抑制变形链球菌生物膜形成。
核心结论
- 研究成功开发出生物相容且稳定的肽GA-C16G2,其在体外对变形链球菌具有快速、强效的选择性抗菌活性。
研究设计与样本
- 本研究为体外实验,将没食子酸(GA)连接到靶向变形链球菌的抗菌肽C16G2上合成新型肽GA-C16G2。
- 采用高效液相色谱(HPLC)测定肽纯度和稳定性,圆二色谱(CD)评估二级结构,PrestoBlue法评估细胞毒性。
- 采用最低抑菌浓度(MIC)和最低杀菌浓度(MBC)试验测定对口腔细菌的抗菌活性,并进行时间-杀菌和生物膜抑制试验。
- 采用透射电镜(TEM)和扫描电镜(SEM)分析细菌形态和生物膜结构。
主要发现
- GA-C16G2合成纯度为95.02%,其二级结构与母肽C16G2高度相似。
- GA-C16G2在人工唾液中稳定性良好,对人牙龈成纤维细胞细胞毒性低。
- GA-C16G2对变形链球菌的MIC为3.1 μM、MBC为20.8 μM,对共生菌作用较弱。
- 时间-杀菌试验显示GA-C16G2在1分钟内使变形链球菌存活率降低97.22%。
- GA-C16G2抑制变形链球菌生物膜形成,TEM和SEM图像证实细菌和生物膜被破坏。
关键数值与推荐
- GA-C16G2对变形链球菌的MIC为3.1 μM、MBC为20.8 μM。
- 时间-杀菌试验中GA-C16G2在1分钟内使变形链球菌存活率降低97.22%。
- GA-C16G2合成纯度为95.02%。
临床怎么用
- GA-C16G2为龋病的靶向预防和治疗提供了一种新的治疗途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to develop a Streptococcus mutans (S. mutans)-targeted peptide for caries management and evaluate its antibacterial efficacy. METHODS: A novel peptide, GA-C16G2, was synthesised by attaching gallic acid (GA) onto an S. mutans-targeted antimicrobial peptide, C16G2. Peptide purity and stability were measured using high-performance liquid chromatography (HPLC). The secondary structure of GA-C16G2 was assessed using circular dichroism (CD) spectroscopy, and cytotoxicity was evaluated with the PrestoBlue assay. Antimicrobial activity against oral bacterial species was determined using minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays. Time-kill and biofilm inhibition assays further characterised the peptide's activity. Bacterial morphology and biofilm structure were analysed by transmission electron microscopy (TEM) and scanning electron microscopy (SEM). RESULTS: GA-C16G2 was synthesised with 95.02 % purity, and its secondary structure closely resembled that of the parent peptide C16G2. GA-C16G2 exhibited good stability in artificial saliva and showed low cytotoxicity towards human gingival fibroblasts. GA-C16G2 demonstrated potent antimicrobial activity against S. mutans (MIC: 3.1 μM, MBC: 20.8 μM) while showing weaker effects against commensal bacterial species. A time-kill assay confirmed the rapid bactericidal activity of GA-C16G2, reducing S. mutans viability by 97.22 % within one minute. GA-C16G2 also inhibited S. mutans biofilm formation. TEM and SEM images confirmed bacterial and biofilm disruption. CONCLUSION: This study demonstrates the successful development of a biocompatible and stable peptide, GA-C16G2, with rapid and potent selective in vitro antimicrobial activity against S. mutans. CLINICAL SIGNIFICANCE: GA-C16G2 offers a novel therapeutic approach for targeted prevention and treatment of dental caries.
引用
- Fu Y, Cannon RD, Li KC, et al. Development and characterisation of a novel antimicrobial peptide GA-C16G2 targeting Streptococcus mutans. J Dent. 2025. PMID: 40578786. doi:10.1016/j.jdent.2025.105927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。